Atazanavir Sulfate and Pitolisant
Determining the interaction of Atazanavir Sulfate and Pitolisant and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4. When studied with midazolam, a probe substrate for CYP450 3A4, pitolisant was found to reduce midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by less than 25%. MANAGEMENT: Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.
Professional:MONITOR: Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4. When studied with midazolam, a probe substrate for CYP450 3A4, pitolisant was found to reduce midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by less than 25%.
MANAGEMENT: Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.
Generic Name: atazanavir
Brand name: Reyataz
Synonyms: Atazanavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Atazanavir Sulfate-Pitolisant Hydrochloride
- Atazanavir Sulfate-Pitressin
- Atazanavir Sulfate-Pitressin Injection
- Atazanavir Sulfate-Pitressin Synthetic
- Atazanavir Sulfate-Placidyl
- Atazanavir Sulfate-Plan B
- Pitolisant-Atelvia
- Pitolisant-Atendia Patch
- Pitolisant-Atenolol
- Pitolisant-Atenolol and chlorthalidone
- Pitolisant-Atenolol and Chlorthalidone Tablets
- Pitolisant-Atenolol Intravenous